Roche receives Swissmedic approval for cancer drug Tecentriq
Published: Friday, Aug 16th 2024, 08:20
Retour au fil d'actualité
The pharmaceutical company Roche has received approval from Swissmedic for a further dosage form of its cancer drug Tecentriq. This means that the PD-L1 cancer immunotherapy can now also be administered as a subcutaneous injection, i.e. under the skin, for various types of cancer.
According to studies, this administration is a clear relief for the patients concerned, as Roche announced on Friday. In particular, the treatment time with this administration is reduced to 3 to 8 minutes per injection, compared to 30 to 60 minutes with a standard infusion - with the same efficacy.
According to Roche, studies also show that the majority of cancer patients prefer subcutaneous treatment because it causes less pain and discomfort, is easier to administer and takes less time than an intravenous infusion.
Tecentriq is approved for some of the most aggressive and difficult-to-treat cancers. These include various types of lung cancer, breast cancer and liver cancer.
©Keystone/SDA
French 
English 
German 
Spanish 
Arabic